When is joint soreness worth a closer look?

Which changes need prompt care?

Get prompt care when one joint becomes hot, very swollen, or hard to move. Fever with those signs makes waiting unsafe.

Quick help also matters when an injured joint cannot support you. A new crooked shape, fast swelling, or sudden weakness needs the same response.

Swelling in the same small joints on both hands can have another cause. Tell a doctor about long morning stiffness, a rash, or sore eyes as well.

These warning signs don't name the cause by themselves. They mean that comparing offices must wait until after a proper exam.

What happens at a regular visit?

The first visit begins with when the soreness started and how it behaves. The clinician may ask about swelling, old injuries, sleep, medicines, and earlier care.

Next comes an exam of motion, strength, and the tender area. Earlier X-rays or scans may help, especially when they show past joint wear.

Leave with clear instructions for care and a date for checking progress. Improvement might mean less pain, longer walks, better sleep, or easier chair rises.

Ask what worsening signs require an earlier call or a different treatment. Keep brief notes and use only the movements that remain comfortable.

Continue that safe motion while waiting for the next visit. QC Kinetix offers regenerative care that may use a prepared portion of your own blood in the sore joint instead of surgery.

Evidence sources

1. The 2010 ACR/EULAR classification criteria define 'definite rheumatoid arthritis' by confirmed synovitis in at least one joint, absence of a better alternative diagnosis, and a total score of 6 or more out of 10 across four domains: number and site of involved joints (0-5), serology (0-3), acute-phase response (0-1) and symptom duration (0-1). This is the formal boundary between inflammatory arthritis and degenerative joint disease.

   Aletaha D, et al. — 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.. Arthritis Rheum, 2010.

2. The 2020 ACR gout guideline issued 42 recommendations including 16 strong ones: start urate-lowering therapy for anyone with tophaceous gout, radiographic damage from gout or frequent flares; allopurinol first-line including in moderate-to-severe chronic kidney disease; low starting doses; and treat-to-target dose titration to a serum urate below 6 mg/dL. Gout is treatable to target in a way osteoarthritis is not.

   FitzGerald JD, et al. — 2020 American College of Rheumatology Guideline for the Management of Gout.. Arthritis Care Res (Hoboken), 2020.

3. The 2025 EULAR update recommends methotrexate, ideally combined with short-term glucocorticoids, as initial therapy for rheumatoid arthritis, within a treat-to-target strategy across conventional synthetic, biological and targeted synthetic DMARDs - a disease-modifying drug pathway that has no counterpart in osteoarthritis and which belongs to rheumatology.

   Smolen JS, et al. — EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.. Ann Rheum Dis, 2026.

4. A Radiology review documents four adverse joint findings structurally observed after intra-articular corticosteroid injection in the hip and knee: accelerated osteoarthritis progression, subchondral insufficiency fracture, complications of osteonecrosis, and rapid joint destruction including bone loss - and notes conflicting evidence on benefit.

   Kompel AJ, et al. — Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought?. Radiology, 2019.